Good list !!. One very compelling argument fo
Post# of 154829
(Total Views: 644)
Posted On: 12/20/2019 11:33:15 AM
Good list !!.
One very compelling argument for the HIV-suffering patients is the fact that there is a COMPOUNDING effect from Leronlimab.
Not only there is no serious AE's but help with compliance (once a week), no tolerance so far, no hepatoxicity and the possibility of slowing and reversing NAFLD (often occurring in HIV patients).
It is extremely difficult to find drugs with no SEAs but, even more difficult, to find drugs that attack two common and associated conditions in an illness.
IMHO this is a "killer" selling argument and should be "song to the four winds", so to speak. The HIV community will embrace Leronlimab with eagerness.
Of course NAFLD alone would be by itself a whole different ball-park. More if it reverses fibrosis a VERY difficult condition to reverse (ask GLMD and GALT).
In the subject of Finesand, she obviously did her DD but faltered on appreciation of the difficulties of closing a deal and let personal appreciations of personalities get in the way. However, I believe that we are only at the beginning of the road and, at these prices CYDY is dirty cheap. I hope she is accumulating as we speak and as she said she was going to do.
There are several subjects that need more detailed discussion including new target prices accounting for new information that we now have and the important revelations in the last conference. Will try to work out some "napkin" calculations, however, I have a very limited number of postings allowed in here (yesterday I couldn't post few comments). Hope will be able to share some.
In any case, let's hope the SP stabilizes, forms a base-line and gets ready for the next leg up. However, current valuations are not representative of the "real price" for any stretch of the imagination.
One very compelling argument for the HIV-suffering patients is the fact that there is a COMPOUNDING effect from Leronlimab.
Not only there is no serious AE's but help with compliance (once a week), no tolerance so far, no hepatoxicity and the possibility of slowing and reversing NAFLD (often occurring in HIV patients).
It is extremely difficult to find drugs with no SEAs but, even more difficult, to find drugs that attack two common and associated conditions in an illness.
IMHO this is a "killer" selling argument and should be "song to the four winds", so to speak. The HIV community will embrace Leronlimab with eagerness.
Of course NAFLD alone would be by itself a whole different ball-park. More if it reverses fibrosis a VERY difficult condition to reverse (ask GLMD and GALT).
In the subject of Finesand, she obviously did her DD but faltered on appreciation of the difficulties of closing a deal and let personal appreciations of personalities get in the way. However, I believe that we are only at the beginning of the road and, at these prices CYDY is dirty cheap. I hope she is accumulating as we speak and as she said she was going to do.
There are several subjects that need more detailed discussion including new target prices accounting for new information that we now have and the important revelations in the last conference. Will try to work out some "napkin" calculations, however, I have a very limited number of postings allowed in here (yesterday I couldn't post few comments). Hope will be able to share some.
In any case, let's hope the SP stabilizes, forms a base-line and gets ready for the next leg up. However, current valuations are not representative of the "real price" for any stretch of the imagination.
(4)
(0)